BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23682827)

  • 21. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.
    Hann IM; Stevens RF; Goldstone AH; Rees JK; Wheatley K; Gray RG; Burnett AK
    Blood; 1997 Apr; 89(7):2311-8. PubMed ID: 9116274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of bone marrow cells grown in long-term culture for autologous bone marrow transplantation in acute myeloid leukaemia: an update.
    Chang J; Morgenstern GR; Coutinho LH; Scarffe JH; Carr T; Deakin DP; Testa NG; Dexter TM
    Bone Marrow Transplant; 1989 Jan; 4(1):5-9. PubMed ID: 2647188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study.
    Steuber CP; Civin C; Krischer J; Culbert S; Ragab A; Ruymann FB; Ravindranath Y; Leventhal B; Wilkinson R; Vietti TJ
    J Clin Oncol; 1991 Feb; 9(2):247-58. PubMed ID: 1988573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
    Stevens RF; Hann IM; Wheatley K; Gray RG
    Br J Haematol; 1998 Apr; 101(1):130-40. PubMed ID: 9576193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia.
    Nakano H; Fujiwara SI; Ito S; Mashima K; Umino K; Minakata D; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Hematol Oncol; 2017 Sep; 35(3):357-364. PubMed ID: 26639319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
    Nørgaard JM; Langkjer ST; Palshof T; Pedersen B; Hokland P
    Eur J Haematol; 2001 Mar; 66(3):160-7. PubMed ID: 11350484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
    Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
    Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.
    Ritter J; Creutzig U; Schellong G
    Haematol Blood Transfus; 1990; 33():185-92. PubMed ID: 2182410
    [No Abstract]   [Full Text] [Related]  

  • 30. Contribution of clonogenic leukemic cell characteristics to therapy outcome in patients with acute myeloblastic leukemia.
    Aul C; Heyll A
    Haematol Blood Transfus; 1987; 30():356-60. PubMed ID: 3476367
    [No Abstract]   [Full Text] [Related]  

  • 31. Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia.
    Nowrousian MR; Pfeiffer R; Schaefer UW; Osieka R; Niederle N; Anders C; Schmidt CG
    Haematol Blood Transfus; 1987; 30():352-5. PubMed ID: 3305206
    [No Abstract]   [Full Text] [Related]  

  • 32. Postremission induction intensive sequential chemotherapy for children with AML--treatment results and prognostic factors.
    Weinstein H; Grier H; Gelber R; Camitta B; Link M; Delorey M; Price K
    Haematol Blood Transfus; 1987; 30():88-92. PubMed ID: 3476388
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.
    Loken MR; Alonzo TA; Pardo L; Gerbing RB; Raimondi SC; Hirsch BA; Ho PA; Franklin J; Cooper TM; Gamis AS; Meshinchi S
    Blood; 2012 Aug; 120(8):1581-8. PubMed ID: 22649108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone marrow fibre content in acute myeloid leukaemia before and after treatment.
    Islam A; Catovsky D; Goldman JM; Galton DA
    J Clin Pathol; 1984 Nov; 37(11):1259-63. PubMed ID: 6594351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cure of acute myeloblastic leukemia in a child with Down syndrome and tetralogy of Fallot].
    Balcar-Boroń A; Nowaczyk-Michalak A; Graduszewska-Czerebiej K
    Wiad Lek; 1992 Mar; 45(5-6):220-3. PubMed ID: 1455866
    [No Abstract]   [Full Text] [Related]  

  • 37. Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
    Lampkin BC; Woods WG; Buckley JD; Hammond GD
    Haematol Blood Transfus; 1990; 33():210-4. PubMed ID: 1691130
    [No Abstract]   [Full Text] [Related]  

  • 38. The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).
    Weinstein H; Ravindranath Y; Krischer J; Steuber P; Civin C; Gresik M; Vietti T
    Leukemia; 1992; 6 Suppl 2():52-4. PubMed ID: 1578941
    [No Abstract]   [Full Text] [Related]  

  • 39. Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts.
    Cesano A; Rosen DB; O'Meara P; Putta S; Gayko U; Spellmeyer DC; Cripe LD; Sun Z; Uno H; Litzow MR; Tallman MS; Paietta E
    Cytometry B Clin Cytom; 2012 May; 82(3):158-72. PubMed ID: 22334473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.
    Quarello P; Fagioli F; Basso G; Putti MC; Berger M; Luciani M; Rizzari C; Menna G; Masetti R; Locatelli F
    Br J Haematol; 2015 Nov; 171(4):566-73. PubMed ID: 26223157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.